重组噬菌体溶菌酶HY-133对金黄色葡萄球菌复合体的不同非洲克隆谱系（包括施氏葡萄球菌）具有体外活性。
The Recombinant Bacteriophage Endolysin HY-133 Exhibits In Vitro Activity against Different African Clonal Lineages of the Staphylococcus aureus Complex, Including Staphylococcus schweitzeri.
作者信息
Idelevich Evgeny A, Schaumburg Frieder, Knaack Dennis, Scherzinger Anna S, Mutter Wolfgang, Peters Georg, Peschel Andreas, Becker Karsten
机构信息
Institute of Medical Microbiology, University Hospital Münster, Münster, Germany.
Hyglos GmbH, Bernried, Germany.
出版信息
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2551-3. doi: 10.1128/AAC.02859-15. Print 2016 Apr.
Abstract
HY-133 is a recombinant bacteriophage endolysin with bactericidal activity againstStaphylococcus aureus Here, HY-133 showedin vitroactivity against major African methicillin-susceptible and methicillin-resistantS. aureuslineages and ceftaroline/ceftobiprole- and borderline oxacillin-resistant isolates. HY-133 was also active againstStaphylococcus schweitzeri, a recently described species of theS. aureuscomplex. The activity of HY-133 on the tested isolates (MIC50, 0.25 μg/ml; MIC90, 0.5 μg/ml; range, 0.125 to 0.5 μg/ml) was independent of the species and strain background or antibiotic resistance.
摘要
HY-133是一种重组噬菌体溶菌酶，对金黄色葡萄球菌具有杀菌活性。在此，HY-133在体外对非洲主要的甲氧西林敏感和耐甲氧西林金黄色葡萄球菌谱系以及头孢洛林/头孢比普和临界耐苯唑西林分离株具有活性。HY-133对施氏葡萄球菌也有活性，施氏葡萄球菌是最近描述的金黄色葡萄球菌复合体中的一个物种。HY-133对测试分离株的活性（MIC50为0.25μg/ml；MIC90为0.5μg/ml；范围为0.125至0.5μg/ml）与物种、菌株背景或抗生素耐药性无关。
相似文献
1
The Recombinant Bacteriophage Endolysin HY-133 Exhibits In Vitro Activity against Different African Clonal Lineages of the Staphylococcus aureus Complex, Including Staphylococcus schweitzeri.重组噬菌体溶菌酶HY-133对金黄色葡萄球菌复合体的不同非洲克隆谱系（包括施氏葡萄球菌）具有体外活性。
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2551-3. doi: 10.1128/AAC.02859-15. Print 2016 Apr.
2
Bactericidal activity of bacteriophage endolysin HY-133 against Staphylococcus aureus in comparison to other antibiotics as determined by minimum bactericidal concentrations and time-kill analysis.通过最低杀菌浓度和时间杀菌分析确定噬菌体溶菌酶HY-133与其他抗生素相比对金黄色葡萄球菌的杀菌活性。
Diagn Microbiol Infect Dis. 2019 Apr;93(4):362-368. doi: 10.1016/j.diagmicrobio.2018.11.005. Epub 2018 Nov 20.
3
In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections.头孢比普对440株从支气管肺部感染分离出的金黄色葡萄球菌的体外活性。
Med Mal Infect. 2017 Mar;47(2):152-157. doi: 10.1016/j.medmal.2016.10.004. Epub 2016 Nov 14.
4
Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).检测亚太地区和南非分离的致皮肤软组织感染和社区获得性呼吸道感染的细菌分离株的抗菌活性：头孢洛林和比较剂（2010 年）。
Diagn Microbiol Infect Dis. 2013 May;76(1):61-8. doi: 10.1016/j.diagmicrobio.2013.01.005. Epub 2013 Mar 25.
5
The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.噬菌体K裂解酶LysK与溶葡萄球菌酶协同作用以杀死耐甲氧西林金黄色葡萄球菌（MRSA）。
FEMS Microbiol Lett. 2008 Oct;287(2):185-91. doi: 10.1111/j.1574-6968.2008.01308.x. Epub 2008 Aug 21.
6
Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees.头孢托罗对近期从美国军事学员中分离出的社区获得性耐甲氧西林金黄色葡萄球菌菌株的活性。
Diagn Microbiol Infect Dis. 2007 Dec;59(4):463-6. doi: 10.1016/j.diagmicrobio.2007.06.023. Epub 2007 Oct 29.
7
In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin.新型抗菌剂 PRF-119（一种重组嵌合噬菌体溶菌素）对金黄色葡萄球菌的体外活性。
Antimicrob Agents Chemother. 2011 Sep;55(9):4416-9. doi: 10.1128/AAC.00217-11. Epub 2011 Jul 11.
8
In vitro activity of ceftaroline against staphylococci from prosthetic joint infection.头孢洛林对人工关节感染患者分离葡萄球菌的体外活性
Diagn Microbiol Infect Dis. 2016 Feb;84(2):141-3. doi: 10.1016/j.diagmicrobio.2015.10.012. Epub 2015 Oct 21.
9
Comparative in vitro activity of bacteriophage endolysin HY-133 against Staphylococcus aureus attached to vascular graft surface.噬菌体溶素 HY-133 对血管移植物表面黏附金黄色葡萄球菌的体外比较活性。
Med Microbiol Immunol. 2020 Feb;209(1):51-57. doi: 10.1007/s00430-019-00638-1. Epub 2019 Oct 17.
10
Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus.重组噬菌体phi11和phi12溶菌酶对金黄色葡萄球菌全细胞和生物膜的裂解活性。
Appl Environ Microbiol. 2007 Jan;73(1):347-52. doi: 10.1128/AEM.01616-06. Epub 2006 Nov 3.
引用本文的文献
1
[Phage endolysins-a novel class of antibacterial agents with a wide range of applications].[噬菌体溶菌酶——一类具有广泛应用的新型抗菌剂]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025 May 6. doi: 10.1007/s00103-025-04059-9.
2
Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications.抗耐药葡萄球菌属的噬菌体衍生内溶素：特性、抗菌活性及近期应用综述
Infect Dis Ther. 2025 Jan;14(1):13-57. doi: 10.1007/s40121-024-01069-z. Epub 2024 Nov 16.
3
The Synergistic and Chimeric Mechanism of Bacteriophage Endolysins: Opportunities for Application in Biotherapeutics, Food, and Health Sectors.噬菌体溶菌酶的协同和嵌合机制：在生物治疗、食品和健康领域的应用机遇
Probiotics Antimicrob Proteins. 2025 Apr;17(2):807-831. doi: 10.1007/s12602-024-10394-1. Epub 2024 Nov 7.
4
Exploration of Bacterial Re-Growth as In Vitro Phenomenon Affecting Methods for Analysis of the Antimicrobial Activity of Chimeric Bacteriophage Endolysins.探索细菌再生长作为一种体外现象对嵌合噬菌体溶菌酶抗菌活性分析方法的影响。
Microorganisms. 2022 Feb 15;10(2):445. doi: 10.3390/microorganisms10020445.
5
Characterization of Clinical MRSA Isolates from Northern Spain and Assessment of Their Susceptibility to Phage-Derived Antimicrobials.西班牙北部临床耐甲氧西林金黄色葡萄球菌（MRSA）分离株的特征分析及其对噬菌体衍生抗菌剂的敏感性评估。
Antibiotics (Basel). 2020 Jul 25;9(8):447. doi: 10.3390/antibiotics9080447.
6
Comparative in vitro activity of bacteriophage endolysin HY-133 against Staphylococcus aureus attached to vascular graft surface.噬菌体溶素 HY-133 对血管移植物表面黏附金黄色葡萄球菌的体外比较活性。
Med Microbiol Immunol. 2020 Feb;209(1):51-57. doi: 10.1007/s00430-019-00638-1. Epub 2019 Oct 17.
7
In Vitro Activity of the Bacteriophage Endolysin HY-133 against Small-Colony Variants and Their Corresponding Wild Types.噬菌体 HY-133 溶菌素对小菌落变异株及其相应野生型的体外活性。
Int J Mol Sci. 2019 Feb 7;20(3):716. doi: 10.3390/ijms20030716.
8
Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials.噬菌体裂解酶治疗细菌性呼吸道感染：新一代抗菌药物。
Front Immunol. 2018 Oct 16;9:2252. doi: 10.3389/fimmu.2018.02252. eCollection 2018.
9
The Novel Phage-Derived Antimicrobial Agent HY-133 Is Active against Livestock-Associated Methicillin-Resistant Staphylococcus aureus.新型噬菌体衍生抗菌剂 HY-133 对畜源耐甲氧西林金黄色葡萄球菌具有活性。
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00385-18. Print 2018 Jul.
10
1st German Phage Symposium-Conference Report.第一届德国噬菌体研讨会-会议报告。
Viruses. 2018 Mar 29;10(4):158. doi: 10.3390/v10040158.
本文引用的文献
1
Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA.PBP2a的错义突变与非洲耐甲氧西林金黄色葡萄球菌（MRSA）对头孢洛林和头孢比普的敏感性降低有关。
J Antimicrob Chemother. 2016 Jan;71(1):41-4. doi: 10.1093/jac/dkv325. Epub 2015 Oct 5.
2
Staphylococcus aureus complex from animals and humans in three remote African regions.来自三个偏远非洲地区的动物和人类的金黄色葡萄球菌复合体。
Clin Microbiol Infect. 2015 Apr;21(4):345.e1-8. doi: 10.1016/j.cmi.2014.12.001. Epub 2014 Dec 11.
3
Novel staphylococcal species that form part of a Staphylococcus aureus-related complex: the non-pigmented Staphylococcus argenteus sp. nov. and the non-human primate-associated Staphylococcus schweitzeri sp. nov.新型葡萄球菌种，属于金黄色葡萄球菌相关复合体：无色葡萄球菌新种和非人类灵长类动物相关的施氏葡萄球菌新种。
Int J Syst Evol Microbiol. 2015 Jan;65(Pt 1):15-22. doi: 10.1099/ijs.0.062752-0. Epub 2014 Sep 30.
4
New epidemiology of Staphylococcus aureus infection in Africa.非洲金黄色葡萄球菌感染的新流行病学。
Clin Microbiol Infect. 2014 Jul;20(7):589-96. doi: 10.1111/1469-0691.12690. Epub 2014 Jul 12.
5
Population dynamics of Staphylococcus aureus from Northeastern Nigeria in 2007 and 2012.2007 年和 2012 年尼日利亚东北部金黄色葡萄球菌的种群动态。
Epidemiol Infect. 2014 Aug;142(8):1737-40. doi: 10.1017/S0950268813003117. Epub 2013 Dec 5.
6
Transmission of Staphylococcus aureus between mothers and infants in an African setting.在非洲环境中，金黄色葡萄球菌在母亲和婴儿之间的传播。
Clin Microbiol Infect. 2014 Jun;20(6):O390-6. doi: 10.1111/1469-0691.12417. Epub 2013 Nov 18.
7
MRSA in Africa: filling the global map of antimicrobial resistance.非洲的耐甲氧西林金黄色葡萄球菌：填补全球抗生素耐药性地图。
PLoS One. 2013 Jul 29;8(7):e68024. doi: 10.1371/journal.pone.0068024. Print 2013.
8
Bacteriophage endolysins as novel antimicrobials.噬菌体溶菌素作为新型抗菌药物。
Future Microbiol. 2012 Oct;7(10):1147-71. doi: 10.2217/fmb.12.97.
9
Drug-resistant human Staphylococcus aureus in sanctuary apes pose a threat to endangered wild ape populations.耐药性人类金黄色葡萄球菌在避难猿类中存在，对濒危野生猿类种群构成威胁。
Am J Primatol. 2012 Dec;74(12):1071-5. doi: 10.1002/ajp.22067. Epub 2012 Aug 21.
10
Epidemiology and population structure of Staphylococcus aureus in various population groups from a rural and semi urban area in Gabon, Central Africa.加蓬农村和半城市地区不同人群中金黄色葡萄球菌的流行病学和种群结构。
Acta Trop. 2012 Oct;124(1):42-7. doi: 10.1016/j.actatropica.2012.06.005. Epub 2012 Jun 28.
Zotero 插件